AtaiBeckley Inc. 8-K

What Happened

• On February 26, 2026, AtaiBeckley Inc. announced positive topline results from its exploratory Phase 2a clinical trial of EMP-01 (oral R‑MDMA) in Social Anxiety Disorder via a press release. The company also scheduled a conference call and webcast to discuss the results at 8:00 a.m. ET on February 26, 2026. The press release and the presentation to be used on the call were furnished as Exhibits 99.1 and 99.2, respectively, to the company’s Form 8-K.

Key Details

• Drug & indication: EMP-01 (oral R‑MDMA) for Social Anxiety Disorder.
• Trial stage: Exploratory Phase 2a; results described as "positive topline."
• Disclosure date/time: Press release and filing dated February 26, 2026; conference call/webcast at 8:00 a.m. ET on February 26, 2026.
• Filings: Press release (Exhibit 99.1) and presentation (Exhibit 99.2) were furnished with the Form 8-K.

Why It Matters

• The company publicly disclosed clinical topline results and is holding a live event to discuss them, making this a near-term catalyst for investor attention. Retail investors who follow AtaiBeckley or clinical-stage psychedelic-based therapies may want to review the furnished materials and listen to the webcast for more detail on efficacy, safety, and next steps.